| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.19 | 6e-07 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.24 | 1e-06 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.14 | 4e-06 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.15 | 9e-06 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.24 | 2e-05 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.12 | 2e-05 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.12 | 7e-05 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |